Press Releases
Palleon Pharmaceuticals Announces NMPA IND Clearance to Proceed with Phase 2 Clinical Trial of E-602 (HLX79), a First-In-Class Treatment for Autoimmune Diseases
Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases
Palleon Pharmaceuticals Presents Results from the Phase 1/2 GLIMMER-01 Trial of E-602 in Combination with Cemiplimab in Patients with Solid Tumors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Palleon to Present New Findings on Colorectal Tumor Microenvironment Identified with its HYDRA Platform at Society for Immunotherapy of Cancer (SITC) Annual Meeting
In the News
AACR-NCI-EORTC 2023: From glycobiology to novel immunotherapeutic approaches
BioWorld Science
Introducing Fierce Biotech’s 2023 Fierce 15
Fierce Biotech
Meet 20 women leaders reshaping biopharma in 2023
Endpoints
Novel strategy of attacking sugars on cancer cells to free immune system shows promise in early tests
STAT